Paraneoplastic Pemphigus (PAMS): Mouth Sores, Skin Signs, and Diagnosis
Paraneoplastic pemphigus (PNP) is a rare autoimmune condition that can cause severe, persistent sores in the mouth and other moist linings, along with a changing rash or blistering eruption. It is associated with an underlying neoplasm, which may be diagnosed before, at the same time as, or after the skin and mucosal symptoms. Because the illness can affect more than the skin, specialists also use the name paraneoplastic autoimmune multiorgan syndrome (PAMS).
The mouth and lips are often the most prominent sites. Skin findings can resemble several different disorders, and some people develop eye, genital, throat, lung, or other organ problems. Diagnosis therefore relies on a combination of examination, biopsy, immune testing, and evaluation for an associated tumor. Persistent mouth sores have many more common causes; they do not by themselves mean that someone has PNP.
What PNP and PAMS mean
PNP is an uncommon autoimmune blistering and inflammatory disease. The immune system produces antibodies and immune cells that react against proteins in epithelial tissues. These proteins help cells attach to one another or anchor the outer layer to deeper tissue. When those connections are disrupted, blisters, erosions, and inflammation can develop.
The word “paraneoplastic” describes an immune effect associated with a tumor; it does not mean that the skin lesions are cancer. Many underlying tumors are related to the blood or lymphatic system, but other benign or malignant growths can occur. PAMS is a broader name that recognizes that autoimmune injury may affect more than skin and visible mucosal surfaces.
Researchers have identified several target proteins, including envoplakin, periplakin, desmoplakin, desmogleins, and other components of epithelial cell structures. Individual antibody profiles vary. The biological picture is complex: antibody activity and cell-mediated inflammation may both contribute to tissue injury. This helps explain why the rash can look different from person to person and why treatment responses can vary.
PNP is rare, and it is seen in adults as well as children. In children, Castleman disease is an important associated condition. In adults, reported associations include non-Hodgkin lymphoma and chronic lymphocytic leukemia, among others. The specific association is not predictable from a rash alone; the clinical team determines what evaluation is appropriate.
Symptoms: mouth sores, skin changes, and more
Persistent sores in the mouth and lips
Severe, painful stomatitis is a hallmark clue. It may involve the inside of the cheeks, gums, tongue, palate, throat, and lips. The affected tissue can become raw, ulcerated, or covered with bloody crusts. In some people, mucosal disease appears before the skin rash and may be the main visible problem for a time.
Pain can make it hard to eat, drink, brush teeth, speak, or sleep. If throat involvement is present, swallowing may become painful. Poor intake can lead to dehydration, weight loss, or malnutrition. A clinician should assess persistent sores that are unusually severe, recur despite treatment, or affect multiple mucosal sites.
Skin findings can take different forms
Skin changes are often polymorphic, meaning that more than one type of lesion may appear. They can develop after the mouth symptoms, at the same time, or less prominently. Possible patterns include fragile blisters and erosions; red or dusky patches resembling erythema multiforme; flat-topped, scaly lichenoid lesions; plaques that resemble graft-versus-host disease; and tense blisters that look like pemphigoid. The scalp, face, trunk, hands, and other areas may be affected.
Because these patterns overlap with common and serious conditions, photographs or online descriptions cannot establish PNP. Clinicians may need to distinguish it from pemphigus vulgaris, mucous membrane pemphigoid, drug reactions such as Stevens–Johnson syndrome, erythema multiforme, lichen planus, infection, and treatment-related mouth inflammation.
Other tissues and organs
Eye, genital, nasal, or throat involvement can cause painful erosions and may scar. In some people, autoimmunity also affects internal epithelial surfaces. The lungs are especially important because bronchiolitis obliterans can cause progressive narrowing and scarring of small airways. New cough, wheezing, or shortness of breath deserves prompt discussion with the care team, particularly when PNP/PAMS is suspected or established.
Other reported findings can involve the gastrointestinal tract or additional organs. Weakness, swallowing difficulty, eye symptoms, and systemic illness should be communicated to the care team rather than attributed automatically to skin disease or cancer treatment.
Why an associated tumor matters
An underlying neoplasm can be known already, discovered during the PNP workup, or found later. In some cases, the mucosal disease is what first brings a person to care. That is why a specialist evaluation can include a search for an associated tumor even when the main complaint is a mouth or skin problem.
The workup is individualized rather than a single universal screening test. Clinicians consider examination findings, age, symptoms, medical history, prior imaging or blood tests, biopsy results, and immune studies. The oncology or hematology team may recommend blood testing, imaging, or a focused assessment for a suspected condition. Follow-up may be needed if no tumor is initially detected but the clinical evidence remains concerning.
A PNP diagnosis does not identify the exact tumor type or stage. It also does not mean every patient has the same cancer, prognosis, or treatment plan. The dermatology and oncology teams interpret the findings together and explain what is known, what remains uncertain, and which next tests are worthwhile.
How doctors diagnose PNP/PAMS
Diagnosis is made by bringing several kinds of evidence together. There is no single appearance or routine blood test that can reliably answer every case. Dermatologists, oral medicine specialists, pathologists, and oncologists may all contribute.
Clinical assessment: The clinician documents how long mucosal sores have lasted, how they responded to prior treatment, which skin patterns are present, whether eyes or genitals are affected, and whether breathing or swallowing has changed. A history of an associated tumor is important but may be absent at first.
Biopsy and tissue staining: A sample from an active skin or mucosal lesion may show a mix of cell separation, interface inflammation, cell injury, or blistering. A separate nearby sample may be sent for direct immunofluorescence. PNP can show intercellular immune staining and deposits along the basement membrane zone, but findings vary by lesion and patient.
Blood and immunologic tests: Indirect immunofluorescence can assess serum binding to specialized tissue substrates, including rat bladder epithelium, which is rich in plakin proteins. Tests for antibodies to envoplakin, periplakin, desmoplakin, or related targets may add important evidence. Some assays are available only at specialized laboratories. Results must be interpreted with the clinical pattern and biopsy; a negative or isolated result is not a complete evaluation.
Evaluation for a neoplasm and organ involvement: Once PNP/PAMS is suspected, the care team considers a targeted workup for a tumor and asks about symptoms that could indicate eye, airway, nutritional, or other complications. Testing is chosen for the individual rather than applying the same imaging or laboratory panel to everyone.
Treatment and supportive care
Care is complex and usually involves multiple specialties. Treatment aims to control the autoimmune inflammation, treat the associated neoplasm, protect affected tissues, manage pain, and prevent infection, dehydration, malnutrition, scarring, or lung injury. There is no one regimen that works for everyone, and response can be difficult to predict.
Treating the associated neoplasm
When a tumor is identified, treatment of that neoplasm is an important part of the plan. Depending on the type and extent, the oncology team may consider surgery, chemotherapy, radiation, targeted therapy, or another approach. Treating the neoplasm may improve the autoimmune disease, but the skin and mucosal inflammation may not resolve immediately and often requires its own management.
Controlling immune activity
Specialists may use systemic corticosteroids, immunosuppressive medicines, B-cell-directed treatment such as rituximab, intravenous immunoglobulin, or other therapies. Plasmapheresis or additional immune treatments may be considered in selected cases. The evidence base is limited because the condition is rare, and no single strategy is appropriate for every patient. Medication decisions depend on tumor type, organ involvement, infection risk, prior treatment, and local expertise.
These treatments can have significant risks. The team may screen for infection, review vaccines, monitor blood counts or organ function, and explain which symptoms require urgent contact. Do not start, stop, or taper prescription immunosuppression without the prescribing clinician.
Protecting the mouth, eyes, skin, and nutrition
Supportive care can be as important as immune treatment. Oral medicine or dentistry may recommend a gentle oral-care plan, pain control, topical treatment, or ways to maintain hydration and nutrition. A dietitian may suggest soft, nutrient-dense foods or nutrition support when chewing and swallowing hurt. Ophthalmology assessment is important for eye symptoms because inflammation can injure the ocular surface and may scar.
Skin care and wound dressings should be selected for fragile erosions and reviewed by clinicians familiar with blistering disease. Gentle handling, reduced friction, and treatment of confirmed infection can protect the barrier. Antibiotics do not treat the autoimmune process and should be used only when a clinician identifies or suspects a bacterial infection.
When to seek care
Arrange prompt evaluation for mouth or lip sores that persist, worsen, affect several sites, or remain difficult to treat—especially if a new skin eruption is also present or there is a history of an associated tumor. A clinician can assess common causes first while deciding whether biopsy or specialized testing is needed.
Contact the care team urgently for new eye redness or pain, painful swallowing, inability to maintain fluids, rapidly spreading erosions, increasing pain, fever, pus, or other signs of infection. Seek emergency care for breathing difficulty, new or worsening shortness of breath, severe weakness, confusion, or signs of significant dehydration.
If PNP/PAMS is already diagnosed, report a new cough, wheeze, chest tightness, or reduced exercise tolerance promptly. Airway complications may not look like a skin flare, and respiratory assessment is important. Follow the plan given by the treating team for after-hours concerns.
How a care plan is coordinated
Because PNP/PAMS can involve a tumor and several tissue types, care often proceeds on parallel tracks. The team first addresses urgent problems such as breathing changes, inability to drink, eye injury, infection, or extensive skin loss. At the same time, specialists confirm the autoimmune diagnosis and determine whether an associated neoplasm is already known or needs investigation.
When a tumor is identified, oncology or hematology clinicians plan treatment for that specific condition. Dermatology and other specialists manage immune-mediated injury, which may need separate treatment even while the tumor is being treated. A change in mouth sores or rash after cancer therapy should be reported: it can reflect PNP activity, infection, a medication effect, or another cause, and the team needs to sort these apart.
Supportive care is planned around the affected sites. Oral medicine may help reduce pain and protect nutrition; ophthalmology evaluates eye symptoms; respiratory clinicians assess cough or breathlessness; and wound-care or nutrition teams may help when skin erosions or oral pain limit everyday function. One clinician should help coordinate follow-up so that new symptoms and treatment side effects are communicated across teams.
Before leaving an appointment, ask who to contact for urgent symptoms, which changes need same-day attention, and how test results will be reviewed. Keep an updated medication list and a record of new symptoms. This does not replace the medical workup, but it can make a complicated care plan easier to follow.
Outlook and follow-up
PNP/PAMS can be serious because it may affect the underlying malignancy, mucosal surfaces, skin barrier, nutrition, eyes, and lungs. The course depends on the associated neoplasm, organ involvement, response to treatment, and complications such as infection. Some patients improve when the tumor is treated and the immune disease is brought under control; others need prolonged multidisciplinary care.
Regular follow-up helps monitor the tumor and the autoimmune disease at the same time. The team may track new skin lesions, oral intake, eye health, breathing symptoms, infections, medication effects, and laboratory or imaging results. Report changes early rather than waiting for a scheduled visit if swallowing, vision, breathing, hydration, or skin pain is getting worse.
For people under evaluation, it is reasonable to ask which diagnosis is most likely, what evidence supports it, what other causes are being considered, which tumor or organ tests are planned, and when results will be reviewed. A written contact plan can help coordinate care across multiple specialties.
Frequently asked questions
Is paraneoplastic pemphigus itself a cancer?
No. Paraneoplastic pemphigus is an autoimmune condition. It is strongly associated with an underlying neoplasm, which may already be known or may need to be investigated; the skin and mucosal disease is not itself a tumor.
Do ordinary mouth ulcers mean I have paraneoplastic pemphigus?
No. Common causes such as infection, trauma, medication effects, and other inflammatory conditions are much more common. Concern rises when painful mouth or lip erosions are severe, persistent, difficult to treat, or accompanied by a varied skin rash or other findings. A clinician evaluates the whole pattern.
Can the rash appear before a tumor is found?
Yes. In some people, mucosal or skin symptoms lead clinicians to look for an associated neoplasm. The timing and type of workup depend on the examination, biopsy, antibody results, age, health history, and any symptoms that suggest a particular tumor.
What tumors are associated with PNP/PAMS?
Associations include lymphoproliferative and hematologic disorders such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Castleman disease, thymoma, and other neoplasms have also been reported. The range differs by age and individual case.
How is paraneoplastic pemphigus confirmed?
Specialists combine clinical findings with skin or mucosal biopsy, direct and indirect immunofluorescence, and blood testing for antibodies such as anti-envoplakin or other plakin proteins. Rat bladder indirect immunofluorescence can be helpful. The suspected underlying neoplasm is assessed in parallel.
Is PNP/PAMS contagious?
No. It is an autoimmune disease and does not spread between people. Open erosions may develop a secondary infection, which is a complication that needs care but does not make the autoimmune condition contagious.
When is urgent care needed?
Seek urgent help for new or worsening shortness of breath, difficulty breathing, severe eye pain or vision changes, inability to swallow fluids, signs of dehydration, fever with rapidly worsening erosions, or feeling seriously unwell. Contact the treating team promptly for rapidly spreading lesions or uncontrolled pain.
References and further reading
- DermNet. Paraneoplastic pemphigus: clinical features, diagnosis, treatment, and outcome.
- Antiga E, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the EADV. J Eur Acad Dermatol Venereol. 2023.
- State-of-the-art diagnosis of autoimmune blistering diseases. Frontiers in Immunology. 2024.
- Paraneoplastic pemphigus: a clinical, laboratory, and therapeutic overview. Anais Brasileiros de Dermatologia.
- Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa. Frontiers in Immunology. 2019.
- Orphanet. Paraneoplastic pemphigus.
Medical information notice: This article is for general education and cannot diagnose PNP/PAMS or an associated neoplasm. Persistent sores and rashes have many causes. Seek assessment from qualified clinicians, and use urgent or emergency care for breathing difficulty, severe eye symptoms, inability to drink, dehydration, or serious illness.
0 comments